Table 3.
Results for measurement of autoantibodies against the four peptides, or all the four peptides in the diagnosis of NSCLC patients
| Index | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPR (%) | NPR (%) |
|---|---|---|---|---|---|
| NSCLC vs healthy | |||||
| Pep A | 0.744 (0.684–0.799) | 46.4 | 90.1 | 91.6 | 41.8 |
| Pep B | 0.809 (0.756–0.854) | 64.0 | 82.0 | 87.5 | 53.7 |
| Pep C | 0.740 (0.684–0.791) | 66.0 | 69.4 | 82.9 | 48.0 |
| Pep D | 0.767 (0.712–0.814) | 78.1 | 62.1 | 80.3 | 59.0 |
| All peptides | 0.821 (0.764–0.868) | 58.1 | 85.3 | 81.0 | 79.6 |
| Early-stage NSCLC4 vs healthy | |||||
| Pep A | 0.706 (0.611–0.790) | 35.1 | 90.1 | 65.3 | 72.5 |
| Pep B | 0.808 (0.732–0.871) | 68.1 | 84.3 | 89.8 | 83.2 |
| Pep C | 0.723 (0.640–0.796) | 73.1 | 69.0 | 59.3 | 80.6 |
| Pep D | 0.780 (0.704–0.843) | 70.4 | 74.7 | 61.3 | 81.5 |
| All peptides | 0.818 (0.719–0.894) | 76.9 | 75.9 | 58.8 | 88.0 |
Note:
4
Defined as NSCLC clinical stage I and II.
Abbreviations: AUC, area under the receiver operating characteristic curve; NPR, negative predictive value; PPR, positive predictive value; NSCLC, non-small cell lung cancer.